Weekly Recap: AZUR-1 primary endpoint hit and Jemperli rights dispute

AnaptysBio, Inc. (NASDAQ:ANAB) reported AZUR-1 met its 12—month primary endpoint and will show data at ESMO Oct 25, 2026, while the company pursues reversal of Jemperli rights in an Oct 20, 2026 hearing as it balances rising legal costs, growing Jemperli royalties (potentially >$390M by 2029) and d…